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Abstract
Background: Acute kidney injury frequently accompanies sepsis. Endotoxin is known to reduce
tissue levels of cAMP and low levels of cAMP have been associated with renal injury. We, therefore,
hypothesized that endotoxin induced renal injury by activating phosphodiesterase 3 (PDE3) which
metabolizes cAMP and that amrinone an inhibitor of PDE3 would prevent the renal injury.
Methods: Animals were divided into three groups (n = 7/group): 1) Control (0.9% NaCl infusion
without LPS); 2) LPS (0.9% NaCl infusion with LPS); 3) Amrinone+LPS (Amrinone infusion with
LPS). Either lipopolysaccharide (LPS) or vehicle was injected via the jugular vein and the rats
followed for 3 hours. We explored the expression of PDE3 isoenzymes and the concentrations of
cAMP in the tissue.
Results:  The PDE3B gene but not PDE3A was upregulated in the kidney of LPS group.
Immunohistochemistry also showed that PDE3B was expressed in the distal tubule in the controls
and LPS caused PDE3B expression in the proximal as well. However, PDE3A was not expressed in
the kidney either in the control or LPS treated groups. Tissue level of cAMP was decreased after
LPS and was associated with an increase in blood urea nitrogen, creatinine, ultrastructural proximal
tubular changes, and expression of inducible nitric oxide synthase (iNOS) in the endotoxemic
kidney. In septic animals the phosphodiesterase 3 inhibitor, amrinone, preserved the tissue cAMP
level, renal structural changes, and attenuated the increased blood urea nitrogen, creatinine, and
iNOS expression in the kidney.
Conclusion: These findings suggest a significant role for PDE3B as an important mediator of LPS-
induced acute kidney injury.
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Background
Acute renal failure (ARF) frequently occurs in the systemic
inflammatory response syndrome. In patients with the
combination of sepsis and ARF mortality is as high as 70%
[1,2]. During endotoxemia, injury to the renal tubule has
been considered to be one of the most important sites
undergoing renal injury [3].
Lipopolysaccharide (LPS) can cause a decrease in tissue
cAMP concentration [4]. An increase in cellular cAMP pro-
tects hypoxemic induced endothelial injury by preserving
its barrier function [5], and improves post-ischemic recov-
ery in the liver and kidney [6,7].
Tissue Cyclic-3',5'-adenosine monophosphate (cAMP)
levels are determined by the balance between activities of
the synthesizing enzyme and the catabolizing enzymes,
such as the cyclic 3',5'-nucleotide phosphodiesterases
(PDE) that hydrolyze the 3'-phosphoester bond of cAMP
to its biologically inactive noncyclic nucleotides 5'-AMP
[8]. Type 3 phsophodiesterase inhibitors (PDEIs) increase
intracellular cAMP by inhibition of phosphodiesterase
enzyme [9]. There are two isogenes, PDE3A and PDE3B,
which differ in their distribution in organ and tissue [10].
The PDE3B gene has been shown to be present in the uro-
genito-epithelium [10].
Lipopolysaccharide (LPS) is one of the important activa-
tors of iNOS (inducible nitric oxide synthase) [11]. Spe-
cific iNOS inhibitors are effective in attenuating kidney
injury with ischemia/reperfusion [12] and with LPS
induced renal dysfunction [13,14]. Although the PDE3
inhibitor, amirinone, reduces LPS stimulated iNOS activ-
iation in vitro [15], its effects on in vivo endotoxemia are
unknown.
The aim of the present study was to examine renal tubular
morphologic changes and renal function occurring in
LPS-induced acute kidney injury in relation to the effect of
LPS on expression of PDE 3A and 3B in the kidney. It was
our hypothesis that LPS would cause renal injury via
PDE3 activation causing catabolism of cAMP leading in
turn to upregulation of iNOS and that the specific PDE3
inhibitor, amrinone [16], would prevent activation of the
cAMP-iNOS pathway with subsequent kidney injury.
Methods
Animal Preparation
Male Sprague Dawley rats weighing between 180 and 230
gm were anesthetized with 80 mg/kg of ketamine and 5
mg/kg of diazepam intraperitoneally. This protocol was
approved by the Keimyung University School of Medicine
and Massachusetts General Hospital Committee on Ani-
mal Research.
Experimental Protocol
Silastic (0.012 inch I.D, 0.025 inch O.D) catheters were
placed in the right jugular vein. Endotoxemia was induced
by administration of E. coli LPS (1 mg/kg; E. coli 0111:B4,
Sigma, St. Luois, MO), single bolus injection through the
jugular vein. The LPS dose was selected from the dose
used in other experiments to induce mild endotoxemia
[17-22]. Animals were divided into three groups (n = 7/
group): 1) Control (0.9% NaCl infusion without LPS); 2)
LPS (0.9% NaCl infusion with LPS); 3) Amrinone+LPS
(Amrinone infusion with LPS). In the amrinone treated
groups, amrinone (Sigma, St. Louis, MO) was continu-
ously infused for 3 h and 15 min at a dose of 40 μg/kg/
min (1 ml/kg/h) [23]. LPS was injected 15 min after start-
ing a continuous infusion of either 0.9% NaCl or amri-
none. In the control and LPS groups, the same volume of
0.9% NaCl (1 ml/kg/h) was infused continuously. The
kidneys were harvested for examination of histopatho-
logic changes (n = 6/group), ultrastructural changes (n =
5/group), and renal tissue cAMP levels (n = 7/group).
Hemodynamic Measurements
Silastic (0.012 inch I.D, 0.025 inch O.D) catheters were
placed in the left carotid artery to monitor systemic artery
pressure on a Gould recorder (Model R53400, Glen
Burnie, MD) and it recorded at 30 minutes intervals.
Reverse transcription-polymerase chain reaction
The expression of PDE3A, PDE3B, and GAPDH was ana-
lyzed by reverse transcription-polymerase chain reaction
(RT-PCR). Total RNA was isolated by using TRIzole rea-
gent. (Gibco BRL, Grand Island, NY). Five micrograms of
total RNA from each specimen were used for complemen-
tary DNA synthesis. The PCR reaction was carried out
using cDNA prepared using reverse transcriptase. The fol-
lowing protocol was used for the PCR: 95°C for 5 min and
35 cycles of 95°C for 30 s 50°C for 30 s and 72°C for 1
min and 30 s. This was followed by a final extension of 10
min at 65°C. PCR with specific forward and reverse regu-
lar or restriction tagged primers was used to amplify PDE
transcripts. The PDE3A forward primer was CTG GCC
AAC CTT CAG GAA TC and the reverse primer was GCC
TCT TGG TTT CCC TTT CTC. The PDE3B forward primer
was AAT CTT GGT CTG CCC ATC AGT CC and the reverse
primer was TTC AGT GAG GTG GTG CAT TAG CTG [24].
Another PDE3A forward primer was CCG AAT TCC CTT
ATC ATA ACA GAA TCC ACG CCA CT and reverse primer
was GGG AAT TCG TGT TTC TTC AGG TCA GTA GCC
[25]. Forward primer for a 528-bp fragment of the house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was ACC ACC ATG GAG AAG GCT GG and
reverse primer was CTC AGT GTA GCC CAG GAT GC. RT-
PCR results were quantified by densitometry using a Bio
RAD imaging densitometer (Model G.S.-690) in conjunc-
tion with Molecular Analyst Software, Version 2.1 (BioBMC Infectious Diseases 2009, 9:80 http://www.biomedcentral.com/1471-2334/9/80
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Rad laboratories, USA). Optical densities were expressed
as arbitrary units.
Blood Urea Nitrogen (BUN) and Serum Creatinine 
Determination
Blood samples were collected from the inferior vena cava
to measure creatinine at the end of the experiment. Blood
samples were centrifuged at 4°C for 15 min at 1200 × g in
glass tubes, and the serum was stored at -80°C in polysty-
rene tubes until use. Estimation of BUN and creatinine
concentration was performed using a creatinine analyzer
(Beckman Instruments, Inc., Fullerton, CA).
Tissue cAMP
Kidney tissue cAMP was measured by a spectrophotomet-
ric colorimetric 96 plate ELISA technique. Briefly, the
renal cortex was immersed in liquid nitrogen, which was
then homogenized in ice-cold 5% trichloroacetic-acid
solution and centrifuged. The supernatant was used for
the analysis of cAMP using an ELISA kit (R&D Systems,
Minneapolis, MN).
Histopathology and Immunohistochemistry
The kidneys were fixed in 10% buffered formalin for 24 h
before processing and embedding into paraffin. Two sec-
tions were cut from each sample and stained with hema-
toxylin and eosin. The paraffin sections were cut to 5 μm
in thickness, mounted on silane-coated glass slides, and
stored for 1 h at 60°C. The slides were deparaffinized with
xylene, three times, 5 min each, and were rehydrated with
graded alcohols (100, 95, 70 and 50%) for 5 min, respec-
tively. After washing with 0.01 M phosphate buffered
saline (PBS) for 5 min, the sections were digested with
Proteinase K (20 μg/ml) at room temperature for 20 min,
and were washed twice with distilled water for 2 min each.
The endogenous peroxidase activity was blocked with 3%
hydrogen peroxide (H2O2) in PBS for 5 min; the slides
were rinsed twice with PBS for 5 min. Sections for positive
control were treated with 3% H2O2  and reacted with
DNase I (1–2 U) at 37°C for 30 min, then washed twice
with PBS. For negative controls, sections were covered
with reaction buffer alone and incubated following same
conditions. The sections were incubated 1.5 h with poly-
clonal antibodies against goat PDE3A and PDE3B
(Abcam, Cambridge, UK) at a concentration of 10 μg/ml.
For microscopic observation, the sections were counter-
stained lightly with hematoxylin for one min.
Electron microscopy
The details for the analysis have been described elsewhere
[26]. The cortical tissues were sliced into small pieces, and
were fixed in periodate lysine paraformaldehyde (PLP)
solution at 4°C overnight. After washing with 0.01 M PBS,
the kidney tissues were immersed in graded concentra-
tions of sucrose in PBS (10% for 1 h, 15% for 2 h, 20% for
4 h) at 4°C. Tissue fragments were post-fixed in
cacodylate buffered 1% OsO4 for 1 h, and embedded in
PolyBed mix resin (Poly/Bed 812, Polysciences Inc., USA).
After trimming the PolyBed mix resin blocks, ultrathin
sections (100 nm) were cut. Sections were examined using
an electron microscope (Hitachi H-7100, Hitachi Co.,
Japan). Five representative areas of five samples per group
were photographed. Two morphologic patterns, intracel-
lular edema and mitochondrial integrity, were graded
with a 5-point scale as follows [27]: 0, no abnormality; 1,
mild lesions affecting 10% or less of kidney samples; 2,
lesions affecting 25% of kidney samples; 3, lesions affect-
ing 50% of kidney samples, and 4, lesions affecting 75%
or more of kidney samples. These evaluations were per-
formed in a blinded fashion.
Immunoblot Analysis for PDE3A and inducible nitric oxide 
synthase
Kidneys from a different group of rats were removed and
immediately frozen in liquid nitrogen 3 hours after LPS
injection. Samples of isolated kidney were lysed in RIPA
buffer (50 μM Tris-HCL [pH 7.5], 150 μM NaCl, 1% Tri-
ton X-100, 1% deoxycholate, and 0.1% sodium dodecyl
sulfate) that contained 25 μg/ml aprotinin, 2 mM sodium
orthovanadate, 25 μg/ml leupeptin, 2 mM phenylmeth-
ysulfonyl fluoride, and 50 mM sodium fluoride for 30
minutes on ice. Lysates were clarified by centrifugation at
15,500 × g for 15 minutes at 4°C. The protein concentra-
tion of the supernatant was measured with a Bio-Rad Pro-
tein Assay Kit. The supernatant was mixed with 2× sample
buffer (114 mM Tris, 9% glycerol, 2.7% sodium dodecyl
sulfate, 0.02% bromophenol blue, and 4.5% mercaptoe-
htanol), boiled for 5 minutes, subjected to 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, and
transferred onto polyvinylidine fluoride (PVDF) mem-
brane (Bio-rad, Hercules, CA). Nonspecific binding sites
were blocked by phosphate-buffered saline (PBS)-0.1%
Tween 20 supplemented with 5% skim milk for 1 hour at
room temperature. The membranes were incubated with
anti-iNOS antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, 1:200) and anti-PDE3A antibody (Abcam,
Cambridge, UK, 1:500) for overnight at 4°C. After exten-
sive washing with three changes of PBS-0.1% Tween 20,
the membranes were incubated with horseradish peroxi-
dase-conjugated secondary for one hour. Immunoreactive
proteins were visualized with an enhanced chemilumines-
cense detection system, followed by exposure to Kodak x-
ray film (Eastman Kodak, Rochester, NY).
Statistical Methods
Analysis was performed using Statview 4.5 (SAS Institute
Inc., Cary, NC). All values were expressed as means ±
standard error of mean. Analysis of variance (ANOVA) for
comparison of the different groups was used with signifi-
cance set at p < 0.05. A significant ANOVA was followedBMC Infectious Diseases 2009, 9:80 http://www.biomedcentral.com/1471-2334/9/80
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by a Scheffe-test for multiple comparisons between
groups. Blood pressure was analyzed by two-way repeated
measures analysis of variance and post hoc tests comparing
group, time and their interactions, with a p < 0.05.
Results
Hemodynamics
Endotoxin and the PDE inhibitor, both may have an effect
on systemic hemodynamics. We monitored mean arterial
pressure (MAP) continuously. At baseline (after anesthe-
sia), MAP showed no differences among the groups (Fig-
ure 1). MAP did not change in the control and LPS groups
throughout the experiment. However, in the amri-
none+LPS group, MAP was mildly but significantly lower
30 min after starting of amrinone infusion compared with
the two other groups. In the amrinone+LPS group, MAP
remained above 80 mm Hg throughout the experiment,
while the other 2 groups MAP stayed above 85 mm Hg.
Expression of PDE3A and PDE3B in the kidney
RT-PCR of kidney tissue was carried out to evaluate mRNA
expression of PDE3 isoenzymes. RT-PCR yielded the
expected size fragment, 300 base pair products, for the
primer pair PDE3B. Although we used two differently
designed fragments for the primer pairs of PDE3A, RT-
PCR did not produce the expected sized fragments of
PDE3A. LPS treatment induced PDE3B mRNA expression
in kidney tissue; it was 9-fold greater than control (Figure
2A). To confirm no expression of the PDE3A enzyme in
the kidney with or without LPS stimulation, we per-
formed immunoblotting of PDE3A. Heart was used for
positive control of PDE3A. PDE3A was expressed neither
in the control kidney nor LPS treated, while it is expressed
in the heart (Figure 2B). This result suggested that PDE3B
gene but not PDE3A was stimulated by LPS in the kidney.
Immunohistochemistry of PDE3
To confirm the RT-PCR results and evaluate structural
localization of PDE3 protein expression in the kidney tis-
sue, we performed immunohistochemistry of the two
PDE3 isoenzymes.
PDE3A was not detectable in both the control (n = 6) and
LPS (n = 6) treated kidneys. However, PDE3B was
expressed in the distal tubule in the control group in all six
kidneys. In the LPS exposed rats, PDE3B is expressed on
both the proximal and distal tubule in all six kidneys.
PDE3B was not present in glomeruli. A typical staining
pattern is demonstrated in Figure 3. These results con-
firmed that PDE3A was not expressed but PDE3B was
expressed in the kidney tissue. The major activating site of
PDE3B protein was the proximal tubule.
Effect of LPS and amrinone on kidney tissue cAMP
There was a significant decrease in cAMP in LPS chal-
lenged kidney tissue at the end of the experiment (saline
120 ± 9 vs. LPS 79 ± 11 pmol/mg protein; n = 7/group; P
< 0.05), a 35% reduction of cAMP level compared with
baseline. Amrinone infusion prevented the fall in kidney
tissue cAMP level leaving it comparable to control (110 ±
5 pmol/mg protein) (Figure 4). These results indicated
that about 75% of the decreased cAMP levels in the LPS
treated tissue was preserved by PDE3 inhibition.
Blood urea nitrogen (BUN) and Creatinine
Renal function was assessed 3 h after administration of
LPS. Renal failure occurred at 3 h as evidenced by a rise in
BUN (saline 21 ± 5 vs. LPS 43 ± 8 mg/dl; P < 0.05) and
serum creatinine levels (saline 0.52 ± 0.05 vs. LPS 0.73 ±
0.04 mg/dl; n = 7/group; P < 0.01). The PDE3 inhibitor,
amrinone, (40 μg/min/kg) significantly attenuated BUN
(27 ± 6 mg/dl; P < 0.05) and creatinine levels (0.58 ± 0.04
mg/dl; P < 0.01) (Figure 5). This suggested that PDE3
inhibition attenuated endotoxin-induced renal failure.
Electron Microscopy
Since light microscopic examination of renal tissue
revealed normal histology, we investigated ultrastructural
changes of the renal proximal tubule. In the control
group, there was well preserved integrity of mitochondria
without cellular edema. However, there was a substantial
change in the mitochondria and in the intracellular
edema in the proximal tubules in the LPS group (Figure
6). Amrinone attenuated the change of mitochondrial
integrity and cellular edema. The result of the numerical
scores and means are presented in Table 1.
Effects of Lipopolysaccharide (LPS) and type 3 phosphodi- esterase (PDE3) inhibitor on mean arterial pressure (MAP) in  rats (n = 7 per group) Figure 1
Effects of Lipopolysaccharide (LPS) and type 3 phos-
phodiesterase (PDE3) inhibitor on mean arterial 
pressure (MAP) in rats (n = 7 per group). PDE3 inhibi-
tor, amrinone, mildly reduced MAP. *P < 0.05 versus Control 
or LPS; †P < 0.05 versus Control.BMC Infectious Diseases 2009, 9:80 http://www.biomedcentral.com/1471-2334/9/80
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Inducible Nitric Oxide Synthase (iNOS) Expression
Administration of LPS significantly increased iNOS pro-
tein in the kidney, while the PDE3 inhibitor significantly
attenuated iNOS protein expression (Figure 7). iNOS was
detected at 130 kD in the kidney tissue from LPS and to a
lesser degree in the amrinone+LPS groups. These results
suggested that there may be an association between PDE3
inhibition and iNOS down regulation.
Discussion
In the present study, we investigated the role of PDE3 in
acute kidney injury induced by endotoxin. Increased
expression of PDE3B along with decreased cAMP in the
exdotoxemic kidneys were associated with reduced renal
function, alteration of renal tubular cell morphology, and
increased iNOS expression. The present data suggested
that the PDE3 inhibitor, amrinone, may have a protective
role in endotoxemic rats with restoration of tissue levels of
cAMP and reduction of iNOS expression, associated with
improved renal function and morphology.
PDE3A is highly expressed in the cardiovascular system,
whereas PDE3B is expressed in adipocytes and hepato-
cytes [10]. In the present study, PDE3B was expressed only
in the distal tubule in the control group, and it was highly
expressed in the proximal tubule when endotoxin was
administered. However PDE3A was not detected in the
kidney in either control or LPS pretreated groups.
Although amrinone is a selective PDE3 enzyme inhibitor,
it does not discriminate between PDE3A and PDE3B [8].
We only found PDE3B in the kidney, and thus presuma-
bly amrinone was inhibiting only PDE3B, suggesting that
PDE3B may have a role in endotoxemic kidney injury.
Lipopolysaccharide (LPS) can cause a decrease in tissue
cAMP concentration [4]. The present study also showed
A representative RT-PCR on total RNA from rat kidneys (A) Figure 2
A representative RT-PCR on total RNA from rat kidneys (A). A representative immunoblotting for PDE3A in the kid-
ney and heart tissue extracts prepared from control and LPS treated group (B). LPS treatment induced 9-fold greater expres-
sion of PDE3B mRNA transcript than control. GAPDH was used as a loading control (A). PDE3A was not detected in the 
kidney tissue either with LPS or without LPS. However, PDE3A was detected in the heart tissue, and LPS caused an increase in 
its expression in the heart (B).BMC Infectious Diseases 2009, 9:80 http://www.biomedcentral.com/1471-2334/9/80
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decreased cAMP concentration in the kidney tissue after
endotoxemia and it was preserved by an infusion of amri-
none. An increased tissue cAMP level has been shown to
protect against hypoxemia induced endothelial injury by
preserving endothelial barrier function [5], to improve
post-ischemic recovery in the liver and kidney [6,7], and
to regulate mitochondrial function [28,29]. Increasing
cAMP attenuates iNOS expression [30]. Therefore, pre-
served cAMP by the PDE3 inhibitor may attenuate iNOS
expression which in turn may reduce endotoxin-induced
kidney injury.
The pathophysiology of sepsis-induced acute renal failure
is still under investigation. Several mediators such as acti-
vated protein C, Caspase 1, Caspase 3, and ICAM-1 do
play a pivotal role in animal models of sepsis-induced
acute kidney injury [31-34]. Activated protein C and cas-
pase 3 were linked to iNOS in a septic kidney model
[31,32]. Sepsis causes vasodilation in the systemic circula-
tion that is mediated by iNOS activation [35]. Peritubular
capillary dysfunction has a significant role in renal cortical
perfusion during endotoxemia [36]. Inhibition of iNOS
by specific iNOS inhibitor has been shown to preserve
renal cortical perfusion during endotoxemia [31]. Futher-
more, upregulation of renal inducible nitric oxide syn-
thase during human endotoxemia and sepsis is associated
with proximal tubule injury [37]. The generation of oxy-
gen radicals during sepsis may cause peroxynitrite-related
tubular injury [3]. In the present study, the PDE3 inhibi-
tor, amrinone, raised tissue levels of cAMP and attenuated
LPS-induced increased renal iNOS protein expression as
well as restoring renal function. Specific iNOS inhibitors
are effective in attenuating kidney injury with LPS induced
renal dysfunction [13,14]. Taken together, downregula-
tion of iNOS by the PDE3 inhibitor may account for atten-
uated proximal tubule damage and preserved renal
function.
PDE3B expression in a control kidney (A) and one treated with LPS (B) Figure 3
PDE3B expression in a control kidney (A) and one treated with LPS (B). In the control group (A), immunohisto-
chemical stain for PDE3B showed positive expression in the epithelial cells of the distal convoluted tubules (arrows). The 
glomerulus and proximal convoluted tubules showed no prominent expression for PDE3B. In the LPS group (B), both proximal 
and distal convoluted tubules showed strong expression for PDE3B (B). PCT: proximal convoluted tubule, DCT: distal convo-
luted tubule, G: glomerulus. Original magnification, ×200.
cAMP concentration (as determined by ELISA) in renal cor- tex at the end of the experiment (n = 7/group) Figure 4
cAMP concentration (as determined by ELISA) in 
renal cortex at the end of the experiment (n = 7/
group). *P < 0.05 versus control or Amrinone+LPS.BMC Infectious Diseases 2009, 9:80 http://www.biomedcentral.com/1471-2334/9/80
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Light microscopic examination of renal tissue revealed
normal histology (data not shown) similar to the findings
of others using high dose of LPS [38,39]. However
ultrastructural changes were present in all endotoxemic
rat kidneys similar to that shown by others [39-41]. In the
proximal tubule, intracellular edema and loss of mito-
chondria integrity were observed in the LPS pretreated rat
kidney. Amrinone infusion attenuated these ultrastruc-
tural change as well as restoring serum BUN and creati-
nine.
In contrast to an earlier study [21], the PDE3 inhibitor is
effective at preventing LPS induced kidney injury. The dif-
ference between the two studies are LPS dose, whether the
rats were anethetized or not, and the use of different types
of PDE3 inhibitor. A lower dose of LPS (1 mg/kg) was
used in the present study compared to the other (4 mg/
kg). Rats were anesthetized in the present study which
may account for the lower baseline MAP and and anesthe-
sia may also lead to less activation of sympathetic nerve
system resulting in less inflammation [42,43]. Further-
more the PDE3 inhibitor, milrinone, was used in the
former study and it is known to have less anti-inflamma-
tory effects [15,21]. Taken together, all of above factors
may contribute conflicting results with the previous study.
Increased cAMP increases muscle contractions in myocar-
dium and relaxation of vascular smooth muscle [44], so
amrinone may lead to lowering of blood pressure.
Although LPS did not cause significant hypotension
throughout the experiment, amrinone significantly
reduced MAP (Fig. 1). However, MAP remained above 80
mm Hg throughout the experiment in the amrinone
group. Therefore the amrinone dose in our study inhib-
Effects of LPS administration and amrinone infusion on serum BUN (A) and creatinine (B) (n = 7/group) Figure 5
Effects of LPS administration and amrinone infusion on serum BUN (A) and creatinine (B) (n = 7/group). *P < 
0.05 versus control or Amrinone+LPS; †P < 0.01 versus control or Amrinone+LPS.
Table 1: Electron microscopy changes in proximal tubules.
Control LPS Amrinone+ LPS
Intracellular edema 0.5 ± 0.2 1.5 ± 0.3* 0.7 ± 0.2
Mitochondrial integrity 0.4 ± 0.2 1.7 ± 0.4* 0.8 ± 0.3
* P < 0.05 versus control or Amrinone+ LPS.BMC Infectious Diseases 2009, 9:80 http://www.biomedcentral.com/1471-2334/9/80
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ited PDE3 without serious hemodynamic changes. Amri-
none inhibits both PDE3A and PDE3B. PDE3A is present
in cardiac muscle and vascular smooth muscle [45] but
was not detectable by us in the kidney, and Amrinone had
little or no effect on kidney function in control rats [46].
PDE3B which is an important regulator of insulin secre-
tory processes and metabolism [47] was found by us in
the kidney. Therefore, the combined positive inotropic
and vasodilating property of amrinone are due to inhibi-
tion of PDE3A. Thus attenuation of LPS induced acute
kidney injury was likely accomplished by inhibition of
PDE3B. Furthermore, amrinone has significant anti-
inflammatory activity independent of its hemodynamic
effects [15,23].
Conclusion
In this study, LPS caused a decrease in renal tissue cAMP
that was associated with an increased expression of
PDE3B, but not PDE3A. The PDE3 inhibitor, amrinone,
averted the fall in tissue cAMP levels, prevented the rise in
iNOS expression, and attenuated the renal tubular injury
induced by LPS. Taken together, it is suggested that PDE3B
inhibition may have a clinical potential in the treatment
of sepsis-induced acute kidney injury.
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